Calcium Supplementation and Management of Hypocalcemia

Acute Symptomatic Hypocalcemia

• Administer 1 g of intravenous calcium gluconate (≈90 mg elemental calcium) over 10–20 minutes with continuous cardiac monitoring; if symptoms persist or calcium remains low, transition to a continuous infusion. (American Society of Endocrinology) 1
• Immediate IV calcium is required for life‑threatening manifestations (seizures, laryngospasm, tetany, bronchospasm) regardless of the measured serum calcium level. (American Society of Endocrinology) 1
• QTc prolongation >0.45 s in men or >0.47 s in women mandates IV calcium irrespective of serum calcium. (American Society of Endocrinology) 1
• Albumin‑corrected serum calcium <7.5 mg/dL (1.9 mmol/L) justifies IV calcium even without severe symptoms. (American Society of Endocrinology) 1
• Patients unable to take oral supplements or with a prior seizure history should receive IV calcium. (American Society of Endocrinology) 1
• Calcium gluconate is preferred over calcium chloride because extravasation causes markedly less tissue necrosis. (American Society of Endocrinology) 1
• Infuse calcium gluconate through a secure, large‑bore IV line to minimize extravasation risk. (American Society of Endocrinology) 1
• Rapid infusion can precipitate cardiac arrest; continuous cardiac monitoring is mandatory throughout administration. (American Society of Endocrinology) 1
• If hypocalcemia persists after the bolus, prepare a continuous infusion of 10 ampules (≈900 mg elemental calcium) in 1 L of 5 % dextrose or normal saline, start at 100 mL/h and titrate to ionized calcium measured every 6 h. (American Society of Endocrinology) 1
• Do not add bicarbonate or phosphate to the infusion solution because they form insoluble calcium salts. (American Society of Endocrinology) 1
• Begin concurrent oral calcium and calcitriol immediately after IV therapy to support sustained repletion. (American Society of Endocrinology) 1

Chronic Hypocalcemia Management

• Target a low‑normal serum calcium (lower half of the reference range) using oral calcium carbonate 1000–1500 mg elemental calcium daily in divided doses plus calcitriol 0.25–0.5 µg twice daily. (American Society of Endocrinology) 2
• Calcium carbonate (≈40 % elemental calcium) is the preferred oral supplement and also serves as a phosphate binder when taken with meals. (American Society of Endocrinology) 2
• Divide the total daily calcium dose into multiple administrations to optimize absorption and reduce gastrointestinal side effects. (American Society of Endocrinology) 2
• Start calcitriol 0.25 µg daily (or alfacalcidol 0.5 µg daily outside the United States) and titrate upward as needed; due to its short half‑life (3–6 h), give in divided doses for better control. (American Society of Endocrinology) 2
• In post‑surgical hypoparathyroidism with severe hypocalcemia, higher initial calcitriol doses (0.25–0.5 µg twice daily) may be required. (American Society of Endocrinology) 2
• Maintain the calcium‑phosphate product <55 mg²/dL² (4.4 mmol²/L²) to prevent ectopic calcifications in brain, kidneys, joints, eyes, skin, and vasculature. (Endocrine Society) 3
• Aim to keep serum calcium in the lower half of normal to minimize hypercalciuria, which rises ~3‑fold after surgery and ~6‑fold in nonsurgical cases. (American Society of Endocrinology) 1

Adjunctive Measures for Hypercalciuria and Hyperphosphatemia

• When 24‑hour urinary calcium exceeds 250 mg (women) or 300 mg (men), add a thiazide diuretic (25–100 mg daily) together with a low‑sodium diet to promote renal tubular calcium retention. (Endocrine Society) 3
• Monitor serum potassium and magnesium during thiazide therapy because these agents cause renal losses of both electrolytes. (Endocrine Society) 3
• Avoid thiazides in patients with autoimmune polyendocrine syndrome type 1 with adrenal insufficiency or autosomal dominant hypoparathyroidism type 1 accompanied by Bartter’s syndrome. (Endocrine Society) 3
• Use calcium‑containing phosphate binders (i.e., calcium carbonate taken with meals) when serum phosphorus is elevated to keep the calcium‑phosphate product below the target threshold. (Endocrine Society) 3
• Implement a low‑phosphate diet if hyperphosphatemia persists despite binders. (Endocrine Society) 3

Monitoring Strategy

• In unstable patients, re‑check serum calcium 4–7 days after any dose adjustment; during active titration, measure serum calcium weekly or monthly based on clinical context. (American Society of Endocrinology) 1
• Consider the timing of oral calcium or calcitriol relative to blood draws, as recent dosing can transiently raise serum calcium levels. (American Society of Endocrinology) 1
• For stable patients, monitor calcium, albumin, phosphorus, magnesium, and eGFR every 3–12 months. (American Society of Endocrinology) 1
• Perform 24‑hour urine calcium and creatinine every 6–24 months; target <250 mg/24 h (women) or <300 mg/24 h (men). (American Society of Endocrinology) 2
• Check 25‑hydroxyvitamin D every 6–12 months to assess vitamin D stores. (American Society of Endocrinology) 2
• Single blood tests may not reflect calcium fluctuations; serial measurements provide a more reliable assessment of control. (American Society of Endocrinology) 1

Recombinant PTH (rhPTH 1‑84) Therapy

Indications

• Consider rhPTH 1‑84 for patients with chronic hypoparathyroidism (excluding autosomal dominant hypocalcemia) who cannot achieve adequate control with calcium and active vitamin D. (Endocrine Society) 3
• Indications include variable calcium control with frequent hypo‑ and hyper‑calcemic episodes, nephrolithiasis/nephrocalcinosis or eGFR ≤ 60 mL/min, persistent hypercalciuria, elevated serum phosphate or calcium‑phosphate product ≥55 mg²/dL², requirement of ≥2.5 g calcium or ≥1.5 g active vitamin D daily, or gastrointestinal disorders affecting absorption. (Endocrine Society) 3

Dosing and Titration

• Start rhPTH 1‑84 at 50 µg once daily subcutaneously (thigh); simultaneously reduce the dose of active vitamin D by 50 % (or oral calcium by 50 %). (Endocrine Society) 3
• Monitor serum calcium within the first week of initiation and after any dose change; adjust dose in 25‑µg increments up to 100 µg daily, with most patients requiring the highest dose. (Endocrine Society) 3

Therapeutic Goals

• Aim to minimize or eliminate active vitamin D, reduce supplemental calcium to ≈500 mg daily, and maintain serum calcium in the lower normal range. (Endocrine Society) 3
• The “triple endpoint” (≥50 % reduction in calcium supplements and active vitamin D while maintaining target serum calcium) was achieved in >50 % of study participants. (Endocrine Society) 3

Safety and Regulatory Considerations

• The FDA approved rhPTH 1‑84 with a black‑box warning due to osteosarcoma findings in rodent studies, but without a duration limit for use. (Endocrine Society) 3
• The indication excludes autosomal dominant hypocalcemia; cost considerations should be part of the decision‑making process. (Endocrine Society) 3

IV Calcium Gluconate Management for Severe Hypocalcemia (Serum Calcium ≤ 6 mg/dL)

Indications

• A serum calcium of 6 mg/dL (≈1.5 mmol/L) constitutes life‑threatening hypocalcemia and mandates urgent intravenous calcium therapy, as it falls well below the 7.5 mg/dL threshold for IV treatment. 4

Initial Bolus Therapy

• Administer 1–2 g of 10 % calcium gluconate (≈90–180 mg elemental calcium) diluted in 50–100 mL of 5 % dextrose or normal saline, infused over 10–20 minutes while maintaining continuous cardiac monitoring; rapid infusion can precipitate cardiac arrest, bradycardia, hypotension, or arrhythmias. 4
• Use a secure, large‑bore peripheral IV line to minimize extravasation risk, which can cause tissue necrosis and calcinosis cutis. 4
• Calcium gluconate is strongly preferred over calcium chloride because extravasation of calcium chloride leads to markedly greater tissue necrosis; calcium chloride should only be administered via a central line if used at all. 4 5

Transition to Continuous Infusion

• After the initial bolus, immediately start a continuous infusion because a single bolus does not sustain normocalcemia in severe hypocalcemia. 4 5
• Prepare the infusion by diluting 10 g (10 ampules) of 10 % calcium gluconate (≈900 mg elemental calcium) in 1 L of 5 % dextrose or normal saline. 4 5
• Begin the infusion at 50–100 mL/hour (≈0.5–1.5 mg/kg/hour elemental calcium). 5
• Do not add bicarbonate or phosphate to the infusion solution, as they form insoluble calcium salts that precipitate. 4

Concurrent Oral Therapy

• Initiate oral calcium carbonate providing 1000–1500 mg elemental calcium daily in divided doses, together with calcitriol 0.25–0.5 µg twice daily, immediately after starting IV therapy to support sustained repletion while the IV infusion is weaned. 4

Monitoring Requirements

• Obtain a 12‑lead ECG to evaluate QTc interval; QTc prolongation (>0.45 s in men, >0.47 s in women) independently mandates IV calcium administration. 4
• Measure serum magnesium, phosphorus, and albumin because hypomagnesemia impairs parathyroid hormone secretion and hyperphosphatemia worsens hypocalcemia. 4
• Continuously monitor for cardiac arrhythmias, laryngospasm, or tetany throughout treatment. 4 5

Target Goals

• Aim for a low‑normal serum calcium level (approximately 8.0–8.5 mg/dL, the lower half of the reference range) to minimize hypercalciuria, nephrocalcinosis, and nephrolithiasis. 5
• Keep the calcium‑phosphate product below 55 mg²/dL² (≈4.4 mmol²/L²) to prevent ectopic calcifications in the brain, kidneys, joints, eyes, skin, and vasculature. 4 5

Safety Considerations

• Do not use calcium chloride peripherally; its high irritancy can cause severe tissue necrosis. 5
• Always check magnesium levels because hypomagnesemia (common in hypocalcemia) hinders effective calcium repletion and must be corrected simultaneously. 4

Management of Life‑Threatening Severe Hypocalcemia

Immediate Intravenous Calcium Therapy

• A serum calcium ≤ 7.5 mg/dL (e.g., 6.9 mg/dL) is classified as life‑threatening and mandates urgent intravenous calcium replacement. 6
• Give 1–2 g of 10 % calcium gluconate (≈90–180 mg elemental calcium) diluted in 50–100 mL of 5 % dextrose or normal saline, infused over 10–20 min while the patient is under continuous cardiac monitoring. 6
• Use calcium gluconate rather than calcium chloride because extravasation of calcium chloride causes markedly greater tissue necrosis; calcium chloride should be reserved for central‑line administration only. 6
• Secure a large‑bore peripheral IV line before infusion to reduce the risk of extravasation. 6
• Maintain continuous cardiac monitoring during the infusion because rapid administration can precipitate bradycardia, hypotension, arrhythmias, or cardiac arrest. 6
• Obtain a 12‑lead ECG immediately; a QTc > 0.45 s in men or > 0.47 s in women independently requires IV calcium regardless of the measured serum calcium level. 6

Transition to Continuous Calcium Infusion

• After the initial bolus, start a continuous calcium infusion because a single bolus does not sustain normocalcemia at this severity. 6
• Prepare the infusion by diluting 10 g (10 ampules) of 10 % calcium gluconate (≈900 mg elemental calcium) in 1 L of 5 % dextrose or normal saline. 6, 7
• Initiate the infusion at 50–100 mL/h (≈0.5–1.5 mg/kg/h elemental calcium) and titrate the rate based on ionized calcium measurements obtained every 6 h. 6, 7
• Do not add bicarbonate or phosphate to the calcium solution because they form insoluble calcium salts that precipitate. 6, 7

Concurrent Oral Calcium and Vitamin D Therapy

• Begin oral calcium carbonate providing 1000–1500 mg elemental calcium per day in divided doses, together with calcitriol 0.25–0.5 µg twice daily, as soon as IV therapy is underway to support sustained repletion while the infusion is weaned. 6

Essential Laboratory Assessment

• Measure serum magnesium promptly; hypomagnesemia impairs parathyroid hormone secretion and hampers calcium correction, so magnesium deficiency must be corrected concurrently. 6
• Measure serum phosphorus to enable calculation of the calcium‑phosphate product. 6
• Measure serum albumin to determine whether total calcium requires albumin‑adjustment (even with severe hypoalbuminemia, a calcium of 6.9 mg/dL reflects true hypocalcemia). 6, 7
• Obtain ionized calcium (preferred monitoring parameter) if the assay is available. 7
• Obtain a baseline parathyroid hormone (PTH) level to differentiate hypoparathyroidism from other etiologies. 8

Target Calcium Goals and Safety Parameters

• Aim for a low‑normal total serum calcium of approximately 8.0–8.5 mg/dL (the lower half of the reference range) to minimize the risk of hypercalciuria, nephrocalcinosis, and nephrolithiasis. 6
• Keep the calcium‑phosphate product below 55 mg²/dL² (4.4 mmol²/L²) to prevent ectopic calcifications in the brain, kidneys, joints, eyes, skin, and vasculature. 6, 8

Monitoring Schedule

• Check ionized calcium every 6 h during continuous infusion and adjust the infusion rate accordingly. 6, 7
• Continuously observe the patient for cardiac arrhythmias, laryngospasm, or tetany throughout acute treatment. 6
• Once the patient is stable, re‑measure total serum calcium 4–7 days after any adjustment of oral therapy. 6
• After stabilization, monitor calcium, albumin, phosphorus, magnesium, and estimated glomerular filtration rate (eGFR) every 3–12 months, depending on clinical stability. 6, 8

Common Pitfalls to Avoid

• Do not overlook hypomagnesemia; correcting magnesium is essential for effective calcium repletion. 6
• Do not target mid‑normal calcium levels in chronic management, as this raises hypercalciuria risk — approximately three‑fold in post‑surgical patients and six‑fold in nonsurgical patients, leading to nephrocalcinosis and chronic kidney disease. 6
• Schedule oral calcium or calcitriol dosing away from blood draws because recent dosing can transiently elevate serum calcium and give a false impression of stability. 6, 7

Diagnostic Workup After Stabilization

• Measure 25‑hydroxyvitamin D to assess vitamin D stores. 8
• Perform a 24‑hour urine collection for calcium and creatinine every 6–24 months, aiming for < 250 mg/24 h in women or < 300 mg/24 h in men. 6, 8

Acute Management of Severe Hypocalcemia

Immediate Clinical Assessment

• Assess patients for neuromuscular and neurologic symptoms of hypocalcemia—including paresthesias, muscle cramps, tetany, positive Chvostek’s or Trousseau’s signs, seizures, or laryngospasm. 9

Intravenous Calcium Therapy

Initial Bolus (not cited) – omitted because no citation

Continuous Calcium Infusion

• Prepare a continuous infusion by mixing 10 ampules (≈10 g) of 10 % calcium gluconate (≈900 mg elemental calcium) in 1 L of 5 % dextrose or normal saline; start the infusion at 50–100 mL/h (≈0.5–1.5 mg kg⁻¹ h⁻¹ elemental calcium) and titrate according to ionized calcium measured every 6 h. 9
• Do not add bicarbonate or phosphate to the infusion solution because they form insoluble calcium salts that precipitate. 9

Essential Laboratory Evaluation

• Measure serum 25‑hydroxyvitamin D levels to assess vitamin D stores when evaluating severe hypocalcemia. 9

Monitoring During Acute Treatment

• Check ionized calcium every 6 hours while the continuous infusion is running and adjust the infusion rate to maintain the target calcium range. 9

Target Biochemical Goals

• Keep the calcium‑phosphate product below 55 mg²/dL² (≈4.4 mmol²/L²) to prevent ectopic calcifications in the brain, kidneys, joints, eyes, skin, and vasculature. 9

Long‑Term Management of Complications

Hypercalciuria

• If 24‑hour urinary calcium exceeds the gender‑specific thresholds, add a thiazide diuretic (25–100 mg daily) together with a low‑sodium diet to enhance renal tubular calcium reabsorption. 9
• While on thiazide therapy, monitor serum potassium and magnesium because thiazides can cause renal losses of these electrolytes. 9
• Avoid thiazide diuretics in patients with autoimmune polyendocrine syndrome type 1 who also have adrenal insufficiency. 9

Persistent Hyperphosphatemia

• Use calcium carbonate taken with meals as a phosphate binder to reduce serum phosphate levels. 9
• If phosphate binders are insufficient, implement a low‑phosphate diet. 9

Vitamin D Repletion and Monitoring in Hypoparathyroidism

25‑Hydroxyvitamin D Target Levels

• Ensure serum 25‑hydroxyvitamin D reaches 30–50 ng/mL (75–125 nmol/L) by prescribing cholecalciferol 1,000 IU daily or ergocalciferol 50,000 IU weekly; adequate stores are required for peripheral conversion to active 1,25‑dihydroxyvitamin D. 10

Calcitriol Dosing Strategy

• Titrate calcitriol upward in 0.25 µg increments; the majority of patients need a total daily dose of 0.5–2 µg, divided into multiple doses, to accommodate its short half‑life of 3–6 hours. 10

Urinary Calcium Surveillance

• Conduct a 24‑hour urinary calcium and creatinine measurement every 6–24 months to identify hypercalciuria in individuals on conventional hypoparathyroidism therapy. 10

Management of Hypoparathyroidism in Autoimmune Polyglandular Syndrome Type 1

Calcium and Vitamin D Replacement

• Target a low‑normal serum calcium of 8.0–8.5 mg/dL (lower half of the reference range) using oral calcium carbonate 1,000–1,500 mg elemental calcium daily in divided doses together with calcitriol 0.25–0.5 µg twice daily. 11
• Calcium carbonate (≈ 40 % elemental calcium) is preferred because it also acts as a phosphate binder when taken with meals. 11
• Split the total daily calcium dose into 3–4 separate administrations to improve intestinal absorption and reduce gastrointestinal side‑effects. 11
• Initiate calcitriol at 0.25 µg daily and increase by 0.25 µg increments; most patients ultimately require 0.5–2 µg daily, divided into multiple doses because of its short 3–6 hour half‑life. 11

Safety Parameters

• Keep the calcium‑phosphate product below 55 mg²/dL² (4.4 mmol²/L²) to avoid ectopic calcifications in the brain, kidneys, joints, eyes, skin, and vasculature. 11

Hypercalciuria Management

• Thiazide diuretics are contraindicated in APS‑1 patients who have adrenal insufficiency; they should not be used to treat hypercalciuria in this group. 11
• In patients without adrenal insufficiency who have 24‑hour urinary calcium > 250 mg (women) or > 300 mg (men), the first‑line intervention is a low‑sodium diet. 11
• If hypercalciuria persists despite sodium restriction, the recommended approach is to reduce calcium supplementation or calcitriol dose rather than adding thiazide diuretics. 11

Monitoring Schedule

• During dose titration, measure serum calcium weekly or monthly according to clinical stability. 11
• Once the regimen is stable, monitor serum calcium, albumin, phosphorus, magnesium, and estimated glomerular filtration rate every 3–12 months. 11
• Perform 24‑hour urine calcium and creatinine every 6–24 months, aiming for < 250 mg/24 h (women) or < 300 mg/24 h (men). 11
• Check 25‑hydroxyvitamin D levels every 6–12 months. 11

Magnesium Considerations

• Do not overlook hypomagnesemia when correcting hypocalcemia, because magnesium deficiency impairs parathyroid hormone secretion and hampers calcium normalization. 11